about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Gene ther­a­py flunks PhII/III study, but for­mer Sarep­ta part­ner sees a path for­ward — if it can find the cash

3 years ago
R&D
Cell/Gene Tx

Alzheimer’s drug bites the dust; Re­struc­ture, re­struc­ture, re­struc­ture; Land­mark di­a­betes OK; and more

3 years ago
Weekly

FDA hits Io­vance with one more de­lay for TIL ther­a­py, ex­tend­ing BLA fil­ing un­til 2023

3 years ago
Cell/Gene Tx
FDA+

Up­dat­ed: Proven­tion prices drug to de­lay type I di­a­betes at $193K as FDA nod kicks off US launch with Sanofi

3 years ago
FDA+

Tenaya bags $75M from stock sale as it pre­pares to put a gene ther­a­py for heart dis­ease in­to the clin­ic

3 years ago
Financing

GSK's cell ther­a­py re­treat hits an­oth­er part­ner as drug­mak­er ex­its Im­mat­ics col­lab­o­ra­tion

3 years ago
Deals
Cell/Gene Tx

Gun­ning for first chikun­gun­ya vac­cine OK, Val­ne­va raids GSK for a sea­soned com­mer­cial chief

3 years ago
People

Astel­las spot­lights PFS, OS win for CLDN18.2 — six years af­ter buy­ing BioN­Tech founder­s' oth­er com­pa­ny for $1.4B

3 years ago
R&D

First came the news of strate­gic re­view. Now Tri­ci­da is let­ting more than half of its staff go in wake of PhI­II flop

3 years ago
People
R&D

Up­dat­ed: Pick­ing up the pieces af­ter lead drug im­plod­ed, Rafael Hold­ings gives up on ear­ly R&D in fa­vor of deals

3 years ago
Deals
R&D

In a step to­ward short­er tu­ber­cu­lo­sis treat­ment, GSK re­ports pos­i­tive mid-stage da­ta for an­tibi­ot­ic

3 years ago
R&D

Up­dat­ed: One down, one to go: Ar­cutis' re­pur­posed As­traZeneca drug clears first PhI­II eczema tri­al

3 years ago
R&D

The crew that sold its lead IL-2 pro­gram to Roche is back with $93M to work on more next-gen I/O drugs

3 years ago
Financing
Startups

Roche dou­bles down on Jnana's drug dis­cov­ery plat­form, kick­ing off sec­ond deal with $50M cash — while biotech bags ...

3 years ago
Financing
Deals

Mod­er­na touts 'su­pe­ri­or' an­ti­body lev­els against Omi­cron for au­tho­rized Covid-19 bi­va­lent boost­er

3 years ago
R&D
Pharma

Aim­ing at main­stream mar­kets, ra­dio­phar­ma­ceu­ti­cal part­ners en­gi­neer $260M cash deal

3 years ago
Deals

Up­dat­ed: Roche hits the brakes on Alzheimer's tri­als af­ter res­ur­rect­ed drug flunks PhI­II

3 years ago
R&D

Bio­gen, Seagen lock in CEOs; 2022 so far — by the num­bers; Phar­ma on Twit­ter; Wave of biotech down­siz­ing ; and more

3 years ago
Weekly

Curis shrinks head­count by 30% as ex­ecs place big­ger hopes on blood can­cer drug

3 years ago
People

Oral al­ter­na­tive to eye in­jec­tions? No­vo backs start­up’s big plan to re­pur­pose shelved drug

3 years ago
Financing
Startups

Fresh out of Flag­ship, David Ep­stein takes the helm at Seagen months af­ter Clay Sie­gall re­signed

3 years ago
People

A can­cer drug un­der clin­i­cal hold, an mR­NA ther­a­py, a kid­ney med: As­traZeneca punts three ear­ly-stage pro­grams

3 years ago
R&D

Catch­ing up with Keytru­da, Re­gen­eron scores front­line NSCLC ap­proval for Lib­tayo/chemo com­bo

3 years ago
Pharma
FDA+

FDA ad­comm of­fers thumbs up on As­traZeneca's 2-in-1 asth­ma in­haler — but on­ly for adults

3 years ago
R&D
FDA+
First page Previous page 20212223242526 Next page Last page
A service from the Financial Times